Oncology Management series: highlights of 2019 – Oncology Central
Here, we discuss some highlights of the last year from across the journal series and look at some hot topics from the area of oncology management.
Related Articles
Biomedical publisher Future Science Group joins Taylor & Francis
Taylor & Francis now becomes the fourth largest publisher of pharma-funded research, with the addition of 32 peer-reviewed FSG journals and five digital hubs.
Biomedical publisher Future Science Group joins Taylor & Francis
Taylor & Francis now becomes the fourth largest publisher of pharma-funded research, with the addition of 32 peer-reviewed FSG journals and five digital hubs.
Biomedical publisher Future Science Group joins Taylor & Francis
Taylor & Francis now becomes the fourth largest publisher of pharma-funded research, with the addition of 32 peer-reviewed FSG journals and five digital hubs.
Cancer care in times of crisis: an interview with Julie Gralow
Julie Gralow discusses sustaining cancer care during natural disasters and times of crisis in this exclusive interview.
LMT 10th Birthday 2022
To celebrate Lung Cancer Management 10th Birthday, we are offering a 25% discount on article processing fees until the end of 2022. Submit your article…
Patient characteristics associated with dose modifications for VRd among newly diagnosed multiple myeloma patients
An article from our partner journal Future Oncolgy explores the characteristics of newly diagnosed multiple myeloma patients with dose modified VRd regimens.
Top 3 Future Oncology articles – October 2022
In the latest instalment of her regular column, Rosanna Zolna, Senior Commissioning Editor of Future Oncology, exclusively shares her top 3 peer-reviewed articles from recent…
The extraordinary case of an individual surviving 12 tumors and the diagnostic opportunities of single-cell analysis
Unique case of individual carrying two mutated versions of MAD1L1 surviving twelve tumors, provides insight into cancer diagnosis earlier than previously imagined.
The extraordinary case of an individual surviving 12 tumors and the diagnostic opportunities of single-cell analysis
Unique case of individual carrying two mutated versions of MAD1L1 surviving twelve tumors, provides insight into cancer diagnosis earlier than previously imagined.
Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas
Here we describe the rationale for, and design of, a clinical study of BI 764532 in patients with small cell lung cancer and other tumors…